Table 2 Demographics and clinical characteristics of patients associated with seizure recurrence, controlling for the competing risk of death (n = 95)
From: Mortality & recurrent seizure risk after new-onset seizure in HIV-positive Zambian adults
| Â | Median time to seizure recurrence [IQR] | P-valuea |
|---|---|---|
Gender | Â | 0.960 |
 Male (n = 13) | 3.1 [1.2–9.3] |  |
 Female (n = 10) | 3.3 [0.5–14.6] |  |
Presenting seizure severity (n = 89) |  | < 0.01 |
 Status epilepticus (n = 17) | 3.1 [1.2–9.3] |  |
 Not status epilepticus (n = 4) | 1.5 [0.4–8.8] |  |
Evidence of seizure focality | Â | 0.339 |
 Yes (n = 14) | 3.1 [1.2–9.3] |  |
 No (n = 9) | 1.1 [0.5–8.8] |  |
WHO clinical stage | Â | 0.334 |
 I or II (n = 4) | 6.4 [1.4–13.5] |  |
 III or IV (n = 19) | 3.1 [0.9–9.3] |  |
cART use | Â | 0.105 |
 Yes (n = 8) | 1.4 [0.3–6.3] |  |
 No, defaulted (n = 4) | 2.8 [1.5–10.0] |  |
 No, never (n = 11) | 8.6 [1.2–15.9] |  |
CSF collected for analysis | Â | 0.845 |
 Yes (n = 20) | 3.5 [0.7–12.6] |  |
 No (n = 3) | 2.6 [2.2–3.7] |  |
CNS opportunistic infection | Â | 0.788 |
 Yes (n = 5) | 9.3 [8.7–15.9] |  |
 No (n = 18) | 5.0 [0.9–8.6] |  |
Unknown seizure etiology | Â | 0.230 |
 Yes (n = 3) | 1.2 [0.03–1.8] |  |
 No (n = 20) | 3.8 [1.1–12.6] |  |